Financial Survey: Helius Medical Technologies (NASDAQ:HSDT) & NeurAxis (NASDAQ:NRXS)

Helius Medical Technologies (NASDAQ:HSDT) and NeurAxis (NASDAQ:NRXS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability.

Insider and Institutional Ownership

18.6% of Helius Medical Technologies shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 7.3% of Helius Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Helius Medical Technologies and NeurAxis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Helius Medical Technologies	-1,374.22%	-221.11%	-86.23%
NeurAxis	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for Helius Medical Technologies and NeurAxis, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Helius Medical Technologies	0	0	1	0	3.00
NeurAxis	0	0	1	0	3.00

Helius Medical Technologies presently has a consensus price target of $54.50, indicating a potential upside of 983.50%. Given Helius Medical Technologies’ higher probable upside, equities research analysts clearly believe Helius Medical Technologies is more favorable than NeurAxis.

Valuation & Earnings

This table compares Helius Medical Technologies and NeurAxis’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Helius Medical Technologies	$640,000.00	6.99	-$8.85 million	($14.46)	-0.35
NeurAxis	$2.46 million	8.41	-$4.78 million	($4.59)	-0.68

NeurAxis has higher revenue and earnings than Helius Medical Technologies. NeurAxis is trading at a lower price-to-earnings ratio than Helius Medical Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

NeurAxis beats Helius Medical Technologies on 7 of the 11 factors compared between the two stocks.

About Helius Medical Technologies

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.

About NeurAxis

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.